跳至主要内容
临床试验/NCT01935557
NCT01935557已完成3 期

Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation

Yong Seog Oh1 个研究点 分布在 1 个国家目标入组 296 人开始时间: 2012年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
296
试验地点
1
主要终点
therapeutic ACT retention rate during procedure

研究概览

简要总结

Optimal anticoagulation using heparin with close attention to maintain therapeutic dosing during the procedure is important.

Randomized comparison of continuous and intermittent heparin infusion during catheter ablation of Atrial Fibrillation.

详细描述

Intravenous heparin was used during the procedure to prevent catheter-induced thrombosis.

heparin is administered during the procedure to achieve recommended activation clotting times (ACT) values, typically >300 seconds to prevent thromboemboli during the procedure.

Most of the practitioners was that ACT level should be checked at 30- to 60-minute intervals and then have injected intermittently.

intermittent heparin infusion, concentration is great changed because the heparin has 30minutes half-period.

researchers postulate that a constant therapeutic concentrations would be beneficial to continuous infusion than intermittent infusion.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

性别
All
接受健康志愿者

入选标准

  • Atrial Fibrillation, Radiofrequency catheter ablation scheduled

排除标准

  • Clinical trial denied

研究组 & 干预措施

Continuous heparin infusion group

Active Comparator

continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.

干预措施: Continuous heparin infusion (Drug)

Intermittent heparin infusion group

Active Comparator

Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.

干预措施: Intermittent heparin infusion (Drug)

结局指标

主要结局

therapeutic ACT retention rate during procedure

时间窗: 2 years

次要结局

未报告次要终点

研究者

发起方
Yong Seog Oh
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yong Seog Oh

Professor

Seoul St. Mary's Hospital

研究点 (1)

Loading locations...

相似试验

Randomized Comparison of Continuous and Intermittent... | 临床试验